This protocol describes the development, expansion, and in vivo imaging of NK cells derived from hESCs and iPSCs.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
* These authors contributed equally
This protocol describes the development, expansion, and in vivo imaging of NK cells derived from hESCs and iPSCs.
We present a method for deriving natural killer (NK) cells from undifferentiated hESCs and iPSCs using a feeder-free approach. This method gives rise to high levels of NK cells after 4 weeks culture and can undergo further 2-log expansion with artificial antigen presenting cells. hESC- and iPSC-derived NK cells developed in this system have a mature phenotype and function. The production of large numbers of genetically modifiable NK cells is applicable for both basic mechanistic as well as anti-tumor studies. Expression of firefly luciferase in hESC-derived NK cells allows a non-invasive approach to follow NK cell engraftment, distribution, and function. We also describe a dual-imaging scheme that allows separate monitoring of two different cell populations to more distinctly characterize their interactions in vivo. This method of derivation, expansion, and dual in vivo imaging provides a reliable approach for producing NK cells and their evaluation which is necessary to improve current NK cell adoptive therapies.
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are undifferentiated, pluripotent cells capable of unlimited self-renewal and multi-lineage differentiation. hESCs have been successfully differentiated into mature and functional subsets of each germ layer, including cells of the hematopoietic system1-3. Natural killer (NK) cells are lymphocytes of the innate immune system that can be derived from hESCs by formation of embryoid bodies (EBs)4,5 or co-culture with stromal cell lines1,2,6-8. NK cells possess anti-viral and anti-tumor capabilities and have the potential to be effective against a broad range of m....
Access restricted. Please log in or start a trial to view this content.
1. Adapting hESCs or iPSCs in TrypLE for Spin EB Cultures
Access restricted. Please log in or start a trial to view this content.
The generation of hematopoietic progenitor cells using the spin EB approach allows for optimal NK cell development from hESCs and iPSCs. As demonstrated in Figure 2, day 11 spin EBs contain high percentages of progenitor cells expressing CD34, CD45, CD43, and CD31. High levels of CD34 and CD45 allows direct transfer to NK conditions without need for sorting or supporting stromal cells. If there is suboptimal spin EB differentiation, it is recommended that stromal cells such as EL08-1D2 are used in the se.......
Access restricted. Please log in or start a trial to view this content.
hESCs are an ideal platform to study diverse cell types and hold remarkable potential for clinical translation. We use a defined, spin EB approach to differentiate hESC/iPSCs to hematopoietic progenitor cells. The spin EB approach has yielded consistent derivation of hematopoietic progenitor cells and differentiation to NK cells; yet, variation still exists in differentiation efficiency across cell lines and may need to be modified for generation of other hematopoietic cell lineages. While comparable results can be obtai.......
Access restricted. Please log in or start a trial to view this content.
This work was supported by NIH/NHLBI R01-HL77923 (D.S.K.) and by NIH MSTP grant T32 GM008244 (D.A.K.), Stem Cell Biology Training Grant T32 (D.A.K.)(T32HD060536), Undergraduate Research Opportunities Program (UROP) Grant, University of Minnesota (A.M.B), the Leukemia Research Fund of the University of Minnesota Cancer Center, and the William L and Blanche Hughes Foundation.
The authors would like to thank Melinda Hexum for initiation of the spin EB protocol within our lab. We would like to thank other members of the lab, including Laura E. Bendzick, Michael Lepley, and Zhenya Ni for their technical assistance with this work. The authors would also like to thank Brad Taylor at Caliper Life Sciences for his expert technical advice.
....Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| Materials | |||
| Media | |||
| BPEL media for Spin EB generation | |||
| Iscove's Modified Dulbecco's Medium (IMDM) | Fisher Scientific | SH3022801 | |
| F-12 Nutrient Mixture w/ Glutamax I | Invitrogen | 31765035 | |
| Bovine Serum Albumin (BSA) | Sigma-Aldrich | A3311 | Commercially available BSA can be cytotoxic to ES cells. Deionizing the solution can reduce the potential for cytotoxicity. |
| Poly(vinyl alcohol) | Sigma-Aldrich | P8136 | |
| Linoleic Acid | Sigma-Aldrich | L1012 | |
| Linolenic Acid | Sigma-Aldrich | L2376 | |
| Synthechol 500X solution | Sigma-Aldrich | S5442 | |
| a-monothioglycerol (a-MTG) | Sigma-Aldrich | S5442 | |
| Protein-free hybridoma mix II | Invitrogen | 12040077 | |
| Ascorbic Acid 2-phosphate | Sigma-Aldrich | A8960 | |
| Glutamax I | Invitrogen | 35050061 | |
| Insulin, Transferrin, Selenium 100X solution (ITS) | Invitrogen | 41400-045 | |
| Pen-Strep | Invitrogen | 15140122 | |
| NK Differentiation Media | |||
| Dubecco's Modified Eagle Medium (DMEM) | Invitrogen | 11965-118 | |
| F-12 Media | Invitrogen | CX30315 | |
| 15% Human AB serum | Valley Biomed | HP1022HI | |
| 5 ng/ml Sodium Selenite | Sigma-Aldrich | S5261 | |
| 50 uM ethanolamine | Sigma-Aldrich | E9508 | |
| 20 ng/ml ascorbic acid | Sigma-Aldrich | A8960 | |
| 25 uM 2-mercapt–thanol (BME) | Gibco | 21985 | |
| 2 mM L-glutamine | Gibco | CX30310 | |
| 1% Pen-Strep | Invitrogen | 15140122 | |
| Cytokines | |||
| (all cytokines used fresh from frozen aliquots) | |||
| SCF | PeproTech, Inc. | 300-07 | 40 ng/ml in BPEL media; 20 ng/ml in NK medium). As noted by the Elefanty protocol, and as we discovered with a bad lot of BMP4, there can be lot differences with cytokines in regards to hematopoietic differentiation.Especially if buying cytokines in bulk, obtain a sample of the lot to test prior to purchase. Compare head-to-head with old lot. |
| rhBMP-4 | R & D Systems | 314-BP | 20 ng/ml in BPEL media |
| rhVEGF | R&D Systems | 293-VE | 20 ng/ml in BPEL media |
| IL-2 | PeproTech, Inc. | 200-02 | 1 x 105 U/ml given to mice after NK cell injection; 50 U/ml used in NK cell expansion protocol |
| IL-15 | PeproTech, Inc. | 200-15 | 10 ng/ml given to mice after NK cell injection (first 7 days only) |
| IL-3 | PeproTech, Inc. | 200-03 | 5 ng/ml in NK media |
| IL-7 | PeproTech, Inc. | 200-07 | 20 ng/ml in NK media |
| Flt-3-Ligand | PeproTech, Inc. | 300-19 | 10 ng/ml in NK media |
| In vivo Imaging | |||
| D-Luciferin Sodium Salt | Gold BioTechnology | Lucna-500 | |
| TurboFP650 plasmid | Evrogen, Moscow, Russia | FP731 | Subcloned into a Sleeping Beauty transposon based plasmid driven by the mCAGs promoter. Cells were then sorted on their expression of turboFP650 by FACS. Cells and plasmids can be obtained from our lab. |
| Equipment | |||
| IVIS Spectrum Imaging System | Caliper Life Sciences | ||
| Cells | |||
| Membrane bound IL-21 expressing artificial antigen presenting cells | MD Anderson, Houston, TX | contact: Dean A. Lee. http://www.jove.com/video/2540/expansion-purification-functional-assessment-human-peripheral-blood | |
| Firefly luciferase expressing hESCs | University of Minnesota, Minneapolis, MN | contact: Dan S. Kaufman . H9 cells modified with a Sleeping Beauty transposon based method (references 13 and 14). Expression of firefly luciferase is driven by the mCAGGS promoter. Following the firefly luciferase gene is an IRES element at the 5' end of a GFP:zeocin fusion construct. | |
| TurboFP650 expressing K562 cells | University of Minnesota, Minneapolis, MN | contact: Dan S. Kaufman. Description under plasmid comments section | |
Materials Table. |
Access restricted. Please log in or start a trial to view this content.